前頭側頭型認知症（FTD）の世界市場

前頭側頭型認知症（FTD）の世界市場は2030年までに3億6,640万米ドルに達する見込み

2024年に2億6,510万米ドルと推定される前頭側頭型認知症（FTD）の世界市場は、2024年から2030年にかけてCAGR 5.5%で成長し、2030年には3億6,640万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである認知機能強化剤は、CAGR 6.6%を記録し、分析期間終了時には1億2,600万米ドルに達すると予測されます。抗精神病薬セグメントの成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は7,220万米ドルと推定、中国はCAGR 8.9％で成長予測

米国の前頭側頭型認知症（FTD）市場は、2024年に7,220万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.9%で推移し、2030年には予測市場規模7,440万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6％と5.5％と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の前頭側頭型認知症（FTD）市場- 主要動向と促進要因のまとめ

前頭側頭型認知症（FTD）が臨床および調査で注目される理由

前頭側頭型認知症（FTD）は、その早期発症、複雑な症状、限られた治療選択肢のため、神経変性疾患研究において重要な注目分野として浮上しています。主に記憶に影響を及ぼすアルツハイマー病とは異なり、FTDは、通常45～65歳という早い時期に、人格、行動、言語に重大な変化をもたらします。非アルツハイマー型認知症に対する認識が高まるにつれ、臨床医は、FTDを、行動変型FTD（bvFTD）や一次性進行性失語症（PPA）など、独自の病理学的亜型を持つ別個の診断対象として認識するようになってきています。

FTDの負担が増大していることから、より良い診断の枠組み、介護者支援、疾患修飾療法が緊急に求められています。FTDは、精神疾患や晩発性うつ病と誤診されることが多いため、FTDを他の神経疾患や精神疾患と鑑別できるバイオマーカーに基づくツールや画像診断を強く求めています。このような開発により、製薬会社や診断薬会社は、十分なサービスを受けていないもの、急速に拡大しているこの疾患分野でイノベーションを起こす機会が生まれています。

診断および治療におけるイノベーションは、疾患管理をどのように変革するのか？

ニューロイメージング、ゲノミクス、分子病理学の進歩により、前頭側頭型認知症（FTD）の診断精度と早期発見が向上しています。PETやMRIによる画像診断技術は、脳の局所萎縮を同定するために改良されつつあり、脳脊髄液（CSF）バイオマーカーや遺伝子プロファイリングは、FTDとアルツハイマー病や他の神経変性疾患との鑑別を可能にしています。タウタンパク質やTDP-43タンパク質のようなバイオマーカーの出現は、FTD治療における精密医療アプローチの道を開きつつあります。

治療面では、研究は対症療法から疾患修飾ターゲットへとシフトしています。パイプラインとなる治療法は、基礎となる蛋白質異常、神経炎症、シナプス機能障害に対処するメカニズムを探求しています。RNAベースの治療薬、アンチセンス・オリゴヌクレオチド（ASO）、タウ凝集阻害剤などが臨床試験に入りつつあり、病気の進行を遅らせたり止めたりすることを目指しています。これと並行して、この病気に伴う認知的・感情的な症状を管理するためのデジタル治療薬や行動介入が開発されています。これらの技術革新は、FTDの臨床的・商業的アプローチ方法におけるパラダイムシフトの舞台を整えつつあります。

標的FTDソリューションの推進を後押しする利害関係者とは？

前頭側頭型認知症（FTD）を取り巻くエコシステムは、学術研究者、バイオテクノロジー企業、患者擁護団体、医療規制当局の関与の高まりを目の当たりにしています。希少疾病の枠組みや希少疾病用医薬品の政策が、この比較的有病率が低いが負担の大きい分野の技術革新を支えています。患者登録と縦断的観察研究は、疾患の進行を理解し、臨床試験デザインを促進し、初期のバイオマーカーを同定するのに役立つ貴重なデータを提供しています。

製薬会社は、FTDのアンメット・メディカル・ニーズを認識し、アルツハイマー病やパーキンソン病の研究を中心に構築された神経変性の研究開発プラットフォームを活用して、FTDの適応症に軸足を移しています。ベンチャーキャピタルからの資金提供や共同コンソーシアムも、ニッチな神経領域でのリードを目指すFTDに特化したバイオテクノロジーに流入しています。デジタル診断や遠隔認知機能評価の役割が高まることで、患者モニタリングの分散化がさらに進み、初期段階や地方の患者に対するケアへのアクセスが拡大しています。

前頭側頭型認知症（FTD）市場の成長を促進する主な要因は？

前頭側頭型認知症（FTD）市場の成長は、診断技術革新、臨床研究の勢い、精密神経学の台頭に関連するいくつかの要因によってもたらされます。最も強力な促進要因の1つは、FTDが明確で過小診断されている疾患であるとの認識が高まっていることであり、これが先進的な神経画像、遺伝子検査、AIベースの診断プラットフォームに対する需要に拍車をかけています。早期発症型認知症の有病率が世界的に上昇する中、正確でタイムリーな診断と個別化されたケア経路に対する対応ニーズが高まっています。

もう一つの重要な推進力は、FTDの病態と重なる神経変性蛋白病、特にタウオ病に焦点を当てた医薬品の研究開発が急増していることです。希少疾病用医薬品の優遇措置、規制当局の迅速な指定、官民の研究パートナーシップの拡大は、FTDを標的とした治療法の開発を加速させています。さらに、現役世代におけるFTDの精神的・経済的負担は、支払者や政策立案者に早期介入戦略や支援サービスの優先順位を促しています。このような力学が交錯することで、市場力学は神経学において大きな影響力を持つ成長フロンティアとして位置付けられています。

セグメント

薬剤クラス（認知機能強化薬、抗精神病薬、抗うつ薬、中枢神経刺激薬、その他の薬剤クラス別）;疾患適応症（前頭側頭型認知症（FTD）、原発性進行性失語症、運動障害）;流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例（計42社）

• Alector Inc.
• Allergan plc
• Apotex Inc.
• Asceneuron SA
• AstraZeneca plc
• AviadoBio Ltd.
• Biogen Inc.
• CervoMed Inc.
• Denali Therapeutics Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Passage Bio, Inc.
• Pfizer Inc.
• Prevail Therapeutics
• Sanofi S.A.
• Wave Life Sciences Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Frontotemporal Dementia Market to Reach US$366.4 Million by 2030

The global market for Frontotemporal Dementia estimated at US$265.1 Million in the year 2024, is expected to reach US$366.4 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Cognitive Enhancers, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$126.0 Million by the end of the analysis period. Growth in the Antipsychotics segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.2 Million While China is Forecast to Grow at 8.9% CAGR

The Frontotemporal Dementia market in the U.S. is estimated at US$72.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.4 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Frontotemporal Dementia Market - Key Trends & Drivers Summarized

Why Is Frontotemporal Dementia Gaining Increasing Clinical and Research Attention?

Frontotemporal dementia (FTD) is emerging as a critical focus area in neurodegenerative disease research due to its early onset, complex symptomatology, and limited treatment options. Unlike Alzheimer’s disease, which primarily affects memory, FTD leads to significant changes in personality, behavior, and language at an earlier age-typically between 45 and 65 years. As awareness of non-Alzheimer’s dementias rises, clinicians are increasingly recognizing FTD as a distinct diagnostic entity with its own set of pathological subtypes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA).

The growing burden of FTD is prompting urgent calls for better diagnostic frameworks, caregiver support, and disease-modifying therapies. Because FTD is often misdiagnosed as psychiatric illness or late-onset depression, there is a strong push toward biomarker-based tools and imaging diagnostics that can differentiate FTD from other neurological or psychiatric disorders. These developments are creating opportunities for pharmaceutical and diagnostic companies to innovate within this underserved but rapidly expanding disease segment.

How Are Diagnostic and Therapeutic Innovations Transforming Disease Management?

Advancements in neuroimaging, genomics, and molecular pathology are enhancing the diagnostic accuracy and early detection of frontotemporal dementia. PET and MRI imaging techniques are being refined to identify regional brain atrophy, while cerebrospinal fluid (CSF) biomarkers and genetic profiling are enabling differentiation of FTD from Alzheimer's and other neurodegenerative conditions. The emergence of biomarkers such as tau and TDP-43 proteins is opening pathways for precision medicine approaches in FTD care.

On the therapeutic front, research is shifting from symptomatic relief toward disease-modifying targets. Pipeline therapies are exploring mechanisms that address underlying proteinopathies, neuroinflammation, and synaptic dysfunction. RNA-based therapies, antisense oligonucleotides (ASOs), and tau aggregation inhibitors are entering clinical trials, aiming to slow or halt disease progression. In parallel, digital therapeutics and behavioral interventions are being developed to manage the cognitive and emotional symptoms associated with the disease. These innovations are setting the stage for a paradigm shift in how FTD is approached both clinically and commercially.

Which Stakeholders Are Driving the Push for Targeted FTD Solutions?

The ecosystem surrounding frontotemporal dementia is witnessing increased engagement from academic researchers, biotech firms, patient advocacy groups, and health regulators. Rare disease frameworks and orphan drug policies are supporting innovation in this relatively low-prevalence yet high-burden segment. Patient registries and longitudinal observational studies are supplying valuable data to aid in understanding disease progression, facilitating clinical trial design, and identifying early biomarkers.

Pharmaceutical companies are recognizing the unmet medical need in FTD and leveraging their neurodegeneration R&D platforms-often built around Alzheimer’s and Parkinson’s research-to pivot into FTD indications. Venture capital funding and collaborative consortia are also flowing into FTD-focused biotechs aiming to lead in niche neurology. The increasing role of digital diagnostics and remote cognitive assessments is further enabling decentralized patient monitoring, widening access to care for individuals in early-stage or rural settings.

What Are the Primary Drivers Fueling Growth in the Frontotemporal Dementia Market?

The growth in the frontotemporal dementia market is driven by several factors related to diagnostic innovation, clinical research momentum, and the rise of precision neurology. One of the most powerful growth drivers is the increasing recognition of FTD as a distinct and underdiagnosed condition, which is spurring demand for advanced neuroimaging, genetic testing, and AI-based diagnostic platforms. As the prevalence of early-onset dementias rises globally, there is a corresponding need for accurate, timely diagnosis and personalized care pathways.

Another key driver is the surge in pharmaceutical R&D focused on neurodegenerative proteinopathies, especially tauopathies, which overlap with FTD pathogenesis. The availability of orphan drug incentives, fast-track regulatory designations, and growing public-private research partnerships are accelerating the development of FTD-targeted treatments. Additionally, the emotional and economic burden of FTD on working-age populations is prompting payers and policymakers to prioritize early intervention strategies and support services. These intersecting dynamics are positioning the frontotemporal dementia market as a high-impact growth frontier in neurology.

SCOPE OF STUDY:

The report analyzes the Frontotemporal Dementia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Other Drug Classes); Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorders); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Alector Inc.
• Allergan plc
• Apotex Inc.
• Asceneuron SA
• AstraZeneca plc
• AviadoBio Ltd.
• Biogen Inc.
• CervoMed Inc.
• Denali Therapeutics Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Passage Bio, Inc.
• Pfizer Inc.
• Prevail Therapeutics
• Sanofi S.A.
• Wave Life Sciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Frontotemporal Dementia - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Aging Population Propels Demand for Specialized Dementia Treatments
  • Advancements in Genetic Research Enhance Understanding of Disease Mechanisms
  • Increased Awareness and Early Diagnosis Initiatives Drive Market Growth
  • Development of Precision Medicine Strengthens Personalized Treatment Approaches
  • Rising Investment in Neurodegenerative Disease Research Fuels Therapeutic Innovations
  • Integration of AI and Telemedicine Improves Patient Monitoring and Care
  • Emergence of Biomarker-Based Diagnostics Enhances Early Detection Capabilities
  • Growing Demand for Non-Pharmacologic Therapies Supports Market Diversification
  • Implementation of Dementia-Friendly Community Programs Encourages Social Inclusion
  • Expansion of Caregiver Support Services Addresses Increasing Care Demands
  • Adoption of Digital Health Records Improves Data Sharing and Patient Management
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Frontotemporal Dementia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Cognitive Enhancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for CNS Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Primary Progressive Aphasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Movement Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• JAPAN
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• CHINA
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• EUROPE
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• FRANCE
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• GERMANY
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• INDIA
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
• AFRICA
  • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030

IV. COMPETITION